News & Updates

A tumour immune barrier (TIB) structure formed by the interaction of SPP1+ macrophages and cancer-associated fibroblasts (CAFs) appears to influence the efficacy of immunotherapy in patients with hepatocellular carcinoma (HCC), reveals a study.

A recent study has found a small-molecule covalently closed circular DNA (cccDNA) inhibitor that reduces levels of hepatitis B virus (HBV) cccDNA. This discovery offers a new way to cure patients with chronic HBV infection.

Time-restricted eating does not appear to be more effective than daily calorie restriction in terms of improving intrahepatic triglyceride content, body fat, and metabolic risk factors for adults with obesity and nonalcoholic fatty liver disease (NAFLD), according to a study.

Use of telbivudine (LdT) during the second trimester of pregnancy helps prevent mother-to-child transmission of hepatitis B virus, reveals a study. In addition, treatment with LdT during pregnancy is safe in the long term for both mothers and infants.

Treatment with the oral Toll-like receptor 8 (TLR8) agonist selgantolimod once weekly for 24 weeks is well tolerated and generally safe in patients with chronic hepatitis B (CHB) under viral suppression, according to a recent study.

Longitudinal changes in fibrosis-4 (FIB-4) score are strongly predictive of progression to cirrhosis and hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD), reveals a study.

Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.

Researchers from the University of Hong Kong (HKU) have developed a nanoparticle-based targeted drug delivery system that selectively transports thyroid hormone (TH) to adipose tissue, which may improve treatment of obesity and its related cardiometabolic complications by overcoming serious adverse events (AEs) associated with systematic TH administration.